πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

83 results for β€œKS” Clear

  1. A first in human study of people with chronic hepatitis B, where all participants will receive the new drug PBGENE-HBV. This study will use increasing dose amounts of the drug to see how safe and bearable it is. The study will also test how well PBGENE-HBV works and how it is processed by the body.

    Chongqing Precision Biotech Co., Ltd

    Chronic Hepatitis B

    phase 1 other active

    1 trial

  2. A first-in-human study to learn about the safety of BAY 3547926 and how well it works in participants with advanced liver cancer

    Bayer AG

    hepatocellular carcinoma (HCC)

    phase 1 other active

    1 trial

  3. A research study looking at how different doses of study medicine (Inno8) works in the body of healthy men.

    NovoThirteen

    Prophylaxis and on-demand treatment respectively in patients with haemophilia A with or without FVIII inhibitors.

    phase 1 other active

    1 trial

  4. A study of how CagriSema works on appetite in people with excess body weight

    NovoThirteen

    Obesity

    phase 1 other active

    1 trial

  5. A study to evaluate how the body absorbs, breaks down and removes drug as well as safety and tolerability when two drugs are administered together as an injection under the skin to healthy participants.

    Janssen-Cilag International N.V.

    Healthy Volunteers

    phase 1 other active

    1 trial

  6. A study to see how RO7763505 works and how safe it is when given to healthy people and people with stable heart disease

    Hoffmann-La Roche

    Stable Coronary Artery Disease (CAD)

    phase 1 other active

    1 trial

  7. A study to test how a new long-acting insulin works in the body of patients with type 2 diabetes during exercise and prolonged fasting.

    NovoThirteen

    Type 2 diabetes

    phase 1 other active

    1 trial

  8. A study to test how insulin NNC0471-0119 H works in the body in participants with type 1 diabetes when given by an insulin pump.

    NovoThirteen

    Diabetes mellitus type 1

    phase 1 other active

    1 trial

  9. A study to test how insulin NNC0471-0119 works in the body in participants with type 2 diabetes when given by an insulin pump.

    NovoThirteen

    Diabetes mellitus type 2

    phase 1 other active

    1 trial

  10. A trial to find out how well CVHNLC works at different dose levels and how safe it is in combination with pembrolizumab in patients with lung cancer that cannot be completely cured.

    CureVac AG

    metastatic squamous non-small cell lung cancer

    phase 1 other active

    1 trial

  11. A trial to learn how saruparib works and how safe it is in the bodies of adults with advanced solid tumors

    AstraZeneca AB

    advanced solid malignancies

    phase 1 other active

    1 trial

  12. A trial to learn if AZD9829 is safe and works alone and in combination with other treatments for participants with certain blood cancers.

    AstraZeneca AB

    CD123-Positive Hematological Malignancies: Module 1 focuses on R/R Acute Myeloid Leukemia and R/R Myelodysplastic Syndrome.

    phase 1 other active

    1 trial

  13. ALKS 33-BUP

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Abuse

    phase 1 small molecule completed

    1 trial

  14. INAVAC (Vaksin Merah Putih - UA- SARS CoV-2 (Vero Cell Inactivated) 5 ΞΌg

    Hospital Authority, Hong Kong

    COVID-19 Pandemic

    phase 1 mab active

    1 trial

  15. KPL-404

    Kiniksa Pharmaceuticals International, plc

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  16. KSH01 injection

    TScan Therapeutics

    TCR-T Cells

    phase 1 small molecule active

    1 trial

  17. KSH01 injection

    TScan Therapeutics

    Solid Tumor

    phase 1 small molecule active

    1 trial

  18. KSHN001126 150mg

    Amneal Pharma Europe Ltd

    Healthy Postmenopausal Women

    phase 1 small molecule completed

    1 trial

  19. KSV01 Injection

    TScan Therapeutics

    Non-Hodgkin Lymphoma

    phase 1 small molecule active

    1 trial

  20. KSV01 Injection

    TScan Therapeutics

    B-ALL

    phase 1 small molecule active

    1 trial

  21. KSX01-TCRT injection

    TScan Therapeutics

    TCR-T Cells

    phase 1 small molecule active

    1 trial

  22. LUCAR-DKS1 NK cells

    Nanjing Legend Biotech Co.

    Relapsed/Refractory Autoimmune Diseases

    phase 1 mab active

    1 trial

  23. Vaksin Merah Putih - UA SARS-CoV-2 (Vero Cell Inactivated) 5 Β΅g

    Hospital Authority, Hong Kong

    COVID-19 Pandemic

    phase 1 mab active

    1 trial

  24. Vicks VapoInhaler

    BRIGHT MINDS BIOSCIENCES INC.

    Opiates

    phase 1 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources